IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants:

Lloyd S. Gray, et al.

Examiner:

Sheela Jitendra Huff

Serial No.:

10/589,216

Art Unit:

1643

Filed:

January 15, 2008

Docket:

18467

For:

INHIBITING CAV3 ISOFORMS

Dated:

July 21, 2008

AND THE δ25B SPLICE VARIENT FOR THE

DIAGNOSIS AND TREATMENT OF CANCER

Confirmation No.: 5782

Commissioner for Patents

P. O. Box 1450

Alexandria, VA 22313-1450

STATEMENT PURSUANT TO 37 C.F.R. § 1.704(d)

Sir:

I hereby state that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart application and that this communication was not received by any individual designated in §1.56(c) more than thirty days prior to the filing of this Information Disclosure Statement.

CERTIFICATE OF ELECTRONIC FILING

I hereby certify that this correspondence is being deposited with the United States Patent & Trademark Office via Electronic Filing through the United States Patent and Trademark Office e-business website.

Dated: July 21, 2008

Peter I. Bernstein

Therefore, this Information Disclosure Statement cannot be considered a failure to engage in reasonable efforts to conclude prosecution of the application under paragraphs (c)(6), (c) (8), (c) (9), or (c) (10) of 37 C.F.R. §1.704.

Respectfully submitted,

Peter I. Bernstein

Registration No. 43,497

Scully, Scott, Murphy & Presser, P.C. 400 Garden City Plaza, Suite 300 Garden City, New York 11530 (516) 742-4343

PIB:dg